EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have been listed as the preferable standard of care in EGFR-mutant NSCLC patients, in particular for lung adenocarcinoma (LUAD). The gene discussed is EGFR; the disease is lung adenocarcinoma.